Replies to post #584024 on NorthWest Biotherapeutics Inc (NWBO)

[iclight]

Do you think the CDER won't have the same questions as doctors being attacked here?

Well we will never know because this company won't possibly submit a BLA with the garbage data when the PI has indicated the need for patient level data in the past.

ASCO 2023. Then ASCO 2024. Feel free to search how many years ASCO has been hyped as the catalyst for this crappy stock. As was the JA. The TLD. Advent being approve to make money for LP from different companies.

Rinse, lather, repeat. For a $0.60 stock.

[skitahoe]

SL,

Presentations in the ASCO conference where an Abstract has been submitted, reviewed and deemed worthy of a presentation are considered a peer reviewed. Once something is peer reviewed the company is free to discuss it. The depth of the review or data presented may not be a great as with a Journal, but companies routinely discuss and present data after it's been presented in a technical conference.

An appearance in the Experts Theater is not considered peer reviewed at all, but the company is free to present data that's previously been peer reviewed there. ASCO won't accept a presentation of information where everything to be presented has already been peer reviewed by others, if something new is added a presentation could be accepted.

The company has a history of presenting at the Experts Theater, I believe corporate personnel make such presentations, though I suppose the clinicians may support them. In the past I believe that the company also had patients who received the vaccine discuss it or at least appear at the Experts Theater. Certainly Drs. attending ASCO may attend the Experts Theater, but it's largely intended to communicate with the investors population.

Gary